{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"93.8","value":"15900"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"AUC0-24h"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.9","value":"24100"},{"groupId":"OG001","spread":"61.2","value":"16100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"AUClast"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Characterize single and multiple-dose PK of LDK378 in pediatric patients. In this phase ceritinib was expanded at 500mg/m2 fed and 510mg/m2 fasted administered orally once daily and was assessed only at steady state, Cycle 2 Day 1.\n\nAUC: Area under the plasma (serum, or blood) concentration versus time curve AUClast: Area under the plasma (serum, or blood) concentration versus time curverea under the concentration-time curve from time zero to the last measureable concentration time AUC0-24h: Area under the plasma concentration-time curve t=0-24 h","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in the fasted group who took 510 mg of ceritinib","id":"OG000","title":"Fasted: Ceritinib 510 mg/m2"},{"description":"Participants in the fed group who took 500 mg of ceritinib","id":"OG001","title":"Fed: Ceritinib 500 mg/m2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set (PAS), MTD/RDE consisted of all patients who received at least one dose of ceritinib and had at least one evaluable PK sample.","reportingStatus":"POSTED","timeFrame":"0hr pre-dose, 2, 4, 6 & 24hrs post-dose","title":"Pharmacokinetics (PK) Parameters: AUC0 - 24h & AUClast in Cycle 2 Day 1 - Dose Expansion Phase (Multiple Dose)","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}